203 related articles for article (PubMed ID: 24824663)
21. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.
Kennedy SH; Rizvi SJ
CNS Drugs; 2010 Jun; 24(6):479-99. PubMed ID: 20192279
[TBL] [Abstract][Full Text] [Related]
22. A benefit-risk assessment of agomelatine in the treatment of major depression.
Howland RH
Drug Saf; 2011 Sep; 34(9):709-31. PubMed ID: 21830835
[TBL] [Abstract][Full Text] [Related]
23. Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case-Control Study Using Automated Health Data Sources.
Pladevall-Vila M; Pottegård A; Schink T; Reutfors J; Morros R; Poblador-Plou B; Timmer A; Forns J; Hellfritzsch M; Reinders T; Hägg D; Giner-Soriano M; Prados-Torres A; Cainzos-Achirica M; Hallas J; Brandt L; Cortés J; Aguado J; Perlemuter G; Falissard B; Castellsagué J; Jacquot E; Deltour N; Perez-Gutthann S
CNS Drugs; 2019 Apr; 33(4):383-395. PubMed ID: 30830574
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal.
Singh SP; Singh V; Kar N
Int J Neuropsychopharmacol; 2012 Apr; 15(3):417-28. PubMed ID: 21859514
[TBL] [Abstract][Full Text] [Related]
25. Agomelatine targets a range of major depressive disorder symptoms.
Dubocovich ML
Curr Opin Investig Drugs; 2006 Jul; 7(7):670-80. PubMed ID: 16869122
[TBL] [Abstract][Full Text] [Related]
26. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review.
Pompili M; Serafini G; Innamorati M; Venturini P; Fusar-Poli P; Sher L; Amore M; Girardi P
World J Biol Psychiatry; 2013 Aug; 14(6):412-31. PubMed ID: 23530731
[TBL] [Abstract][Full Text] [Related]
27. Agomelatine: efficacy at each phase of antidepressant treatment.
Kennedy SH
CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725
[TBL] [Abstract][Full Text] [Related]
28. Addressing circadian rhythm disturbances in depressed patients.
Lam RW
J Psychopharmacol; 2008 Sep; 22(7 Suppl):13-8. PubMed ID: 18753278
[TBL] [Abstract][Full Text] [Related]
29. Agomelatine: a novel pharmacological approach to treating depression.
Owen RT
Drugs Today (Barc); 2009 Aug; 45(8):599-608. PubMed ID: 19927226
[TBL] [Abstract][Full Text] [Related]
30. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.
Lôo H; Hale A; D'haenen H
Int Clin Psychopharmacol; 2002 Sep; 17(5):239-47. PubMed ID: 12177586
[TBL] [Abstract][Full Text] [Related]
31. Agomelatine in the treatment of seasonal affective disorder.
Pjrek E; Winkler D; Konstantinidis A; Willeit M; Praschak-Rieder N; Kasper S
Psychopharmacology (Berl); 2007 Mar; 190(4):575-9. PubMed ID: 17171557
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerance profile of agomelatine and practical use in depressed patients.
Rouillon F
Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S31-5. PubMed ID: 16436938
[TBL] [Abstract][Full Text] [Related]
34. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development.
de Bodinat C; Guardiola-Lemaitre B; Mocaër E; Renard P; Muñoz C; Millan MJ
Nat Rev Drug Discov; 2010 Aug; 9(8):628-42. PubMed ID: 20577266
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression.
Stein DJ; Picarel-Blanchot F; Kennedy SH
Hum Psychopharmacol; 2013 Mar; 28(2):151-9. PubMed ID: 23532747
[TBL] [Abstract][Full Text] [Related]
36. How to switch to agomelatine after an unsuccessful try with paroxetine or venlafaxine.
Lejoyeux M; Matharan S; de Bodinat C
CNS Spectr; 2015 Feb; 20(1):29-38. PubMed ID: 24330826
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy of agomelatine in depression: the evidence.
den Boer JA; Bosker FJ; Meesters Y
Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S21-4. PubMed ID: 16436936
[TBL] [Abstract][Full Text] [Related]
38. Agomelatine: a review of adverse effects.
Prescrire Int; 2013 Mar; 22(136):70-1. PubMed ID: 23593692
[TBL] [Abstract][Full Text] [Related]
39. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine.
Montgomery SA; Kasper S
Int Clin Psychopharmacol; 2007 Sep; 22(5):283-91. PubMed ID: 17690597
[TBL] [Abstract][Full Text] [Related]
40. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
Goodwin GM; Emsley R; Rembry S; Rouillon F;
J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
